Relay Therapeutics (NasdaqGM:RLAY) plans to move its lead program, zovegalisib, into Phase 3 development for frontline PI3Ka ...
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline developmentCompelling efficacy and tolerability data for zovegalisib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results